
Centessa Pharmaceuticals plc
NASDAQ:CNTA
16.79 (USD) • At close August 29, 2025
Overzicht | Financiële gegevens
Bedrijfsnaam | Centessa Pharmaceuticals plc |
Symbool | CNTA |
Munteenheid | USD |
Prijs | 16.79 |
Beurswaarde | 2,248,408,605 |
Dividendpercentage | 0% |
52-weken bereik | 9.6 - 19.09 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Saurabh Saha M.D., Ph.D. |
Website | https://www.centessa.com |
An error occurred while fetching data.
Over Centessa Pharmaceuticals plc
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor,
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)